Noninvasive test for adrenal function in children and adults
Official title: NeSST2: A Multi-stage Clinical Study to Develop a Non-invasive Short Synacthen Test (SST)
Run by Sheffield Children's NHS Foundation Trust · NCT03514589 · Data updated 2026-11-12
This study is testing a new noninvasive way to check how well the adrenal glands are working in children and adults who use inhaled steroids, to see if it’s safer and easier than the traditional method.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 6 Months to 60 Years |
| Sex | Men only |
| Enrollment | 12 (estimated) |
| Sponsor | Sheffield Children's NHS Foundation Trust Academic / other |
| Locations | 1 site (Sheffield, Sheffield (South Yorkshire District)) |
| Status | Recruiting |
| Started | October 12, 2012 |
| Main results expected | December 1, 2025 |
| Study ends | December 1, 2025 |
| Registry record updated | December 3, 2024 |
| Trial ID | NCT03514589 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include healthy adults aged 18-64 and children aged 0-15 years who are prescribed inhaled corticosteroids.
✕Probably not a fit
Patients with a history of endocrinopathy or those currently suffering from asthma or allergic rhinitis may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to develop a noninvasive Short Synacthen Test (SST) to assess adrenal function in individuals, particularly focusing on children who are prescribed inhaled corticosteroids. The study will evaluate the pharmacokinetics of nasal Tetracosactide in both healthy adults and children, comparing it to the traditional intravenous method. By conducting this research, the trial seeks to establish a safer and more practical method for monitoring adrenal suppression, which can occur due to long-term steroid use. The trial will involve multiple visits to a specialized children's clinical research facility to gather necessary data.
Why it matters
Potential benefit: If successful, this study could provide a safer, noninvasive method for monitoring adrenal function in patients using inhaled corticosteroids.
How similar studies have gone: While the approach of using a noninvasive method for adrenal function testing is innovative, similar studies have shown promise in assessing adrenal suppression in other contexts.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Stage 1b+c: • Healthy, male volunteers aged between 18-64 with none of the exclusion criteria listed below. Stage 2: • Healthy children of either sex, aged between 2 and 15 years (up to their 16th birthday) with none of the exclusion criteria listed below. Stage 3: • Healthy children of both sexes, aged between 0-18 years without exclusion criteria 1,2,3,5,6,7,8,9,10,11,12,14 listed below. Stage 4: • Asthmatic children of both sexes, aged between 6 months and 15 years, prescribed regular inhaled corticosteroids and without exclusion criteria 1,5,9,10,11,12, and 14 listed below. Exclusion Criteria: 1. Past or present history of an endocrinopathy (all stages) 2. Past or present history of asthma (stages 1b+c,2,3) 3. Past or present history of allergic rhinitis (stages 1b+c,2,3) 4. Past or present history of peptic ulcer disease/GI bleed/significant dyspepsia (stages 1b+c,2) 5. Past history of intra-cranial or renal/adrenal pathology (all stages) 6. Presently on any medication (stages 1b+c,2,3) 7. Presently, or within the last 3 months, been prescribed any type of corticosteroid (oral, inhaled, nasal, rectal, intravenous, intramuscular, intra-articular, intra-ocular, topical) (stages 1b+c,2,3) 8. Ever been prescribed a prolonged course of oral corticosteroids (more than 1 month) (stages 1b+c,2,3) 9. Previous adverse reaction (including mild hypersensitivity) to ACTH or Synacthen (all stages) 10. Previous severe allergic reaction or anaphylaxis (all stages) 11. Coryzal symptoms within the last week (and will be asked to report any new symptoms occurring within 24 hours of the test) (all stages) 12. Current smoker (all stages) 13. Body Mass Index less than 18.5 or more than 30kg/m2 (stages 1b+c) outside 3rd to 97th centiles for ages and sex (stage 2) 14. Currently pregnant (stages 2,3,4) 15. Currently anaemic (stages 1b+c,2)
Where it's running
-
Sheffield Children's NHS Foundation Trust
Sheffield, Sheffield (South Yorkshire District), United Kingdom Recruiting
Study contacts
- Principal investigator: Charlotte Elder — Investigator
- Study coordinator: Meena Balasubramanian
- Email: meena.balasubramanian@nhs.net
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
SleepCogni for children with chronic insomnia
A handheld SleepCogni device is tested to see if it helps kids aged 6–16 with chronic insomnia sleep better.
-
PANDA-ASOCT: Detecting Uveitis in Children with Automated Eye Image Analysis
This study tests a high-speed, non-invasive eye imaging system with automated analysis to help detect uveitis in children and young people who attend a clinic for uveitis or juvenile idiopathic arthritis.
-
Lung MRI for children with protracted bacterial bronchitis (PBB)
We will try using MRI to look at the lungs of children aged 5–17 with suspected PBB so they might avoid anaesthesia and radiation from bronchoscopy and CT.
-
Dexamethasone dosing for children with acute asthma in the emergency department
This study tests whether two different single doses of dexamethasone given in the emergency department help children aged 4–15 during an asthma attack.
-
High-resolution infrared imaging to detect bone, joint and soft-tissue infections in children
We will test whether a 10-second high-resolution infrared thermal video can help detect bone, joint, or soft-tissue infections in children up to 15 years old.
-
Using PET-MRI to monitor brain tumors in children
This study is testing if a new type of brain scan called PET-MRI can help doctors better monitor children with brain tumors after treatment to see if the tumors come back or get worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.